Advertisement Aegerion completes acquisition of Myalept from AstraZeneca - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Aegerion completes acquisition of Myalept from AstraZeneca

Aegerion Pharmaceuticals has completed the acquisition of AstraZeneca’s Myalept (metreleptin) for injection, an orphan drug product to treat complications of leptin deficiency in patients with generalized lipodystrophy (GLD).

Myalept is a recombinant human leptin analog indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired GLD.

Aegerion chief executive officer Marc Beer said: "We are excited to have an opportunity to build on AstraZeneca’s progress and commitment to delivering Myalept to GLD patients, with a continuing commitment to excellence in patient support."

The acquisition follows the asset purchase agreement that was announced on 6 November 2014.

As part of the deal, Aegerion paid $325m upfront to acquire the global rights to develop, manufacture and commercialize Myalept. This is subject to an existing distributor licence with Shionogi covering Japan, South Korea and Taiwan.

Myalept is the first and only product approved in the US to treat GLD and has orphan drug designation in the US, EU, and Japan.